Urolithin A for Longevity: The Science Behind Mitophagy, Immune Aging, and Mitopure

Mitochondria are the power plants of every cell in your body. They convert oxygen and nutrients into ATP — the energy currency that runs everything from muscle contractions to immune responses to cognitive processing. At their peak, your mitochondria are remarkably efficient, producing energy continuously with minimal waste. The problem is that peak does not last.

As you age, mitochondria accumulate damage — from oxidative stress, metabolic byproducts, and replication errors in mitochondrial DNA. Your cells have a built-in quality control system called mitophagy — a selective form of autophagy that identifies damaged mitochondria and removes them before they can contaminate surrounding, healthy organelles. Think of mitophagy as a cellular recycling program: flag the broken machinery, break it down, and use the salvaged materials to build new, functional mitochondria.

The problem with aging is that mitophagy slows down. Damaged mitochondria accumulate faster than they are cleared. Cells increasingly rely on dysfunctional mitochondria that produce less energy and more reactive oxygen species. The result is a cascade of decline: reduced energy metabolism, impaired immune function, muscle weakness, slower recovery, and rising systemic inflammation — the condition researchers call inflammaging. Virtually every system associated with healthy aging is downstream of mitochondrial quality.

This is why mitophagy is now considered one of the key levers in the biology of aging. And it is why urolithin A — the most potent naturally derived mitophagy inducer identified in human research — has become one of the most discussed longevity compounds of the last several years.

Urolithin A is not a nutrient you eat directly. It is a compound your gut bacteria produce by metabolizing ellagitannins and ellagic acid — polyphenols found primarily in pomegranates, walnuts, and red raspberries. The conversion pathway requires specific Gordonibacter and Ellagibacter species in your gut microbiome, along with the right biochemical conditions. Get all of this right, and your gut can convert dietary ellagitannins into urolithin A, which then enters your bloodstream and triggers mitophagy in muscle, immune, and other cells.

Here is the catch: research consistently shows that the human population splits into three distinct urolithin producer groups. Roughly 40% of people are high producers who generate meaningful urolithin A from normal dietary sources — usually people with greater gut microbiome diversity and the right Gordonibacter species. Another 30–40% are low producers who generate small, subclinical amounts. And 20–30% are non-producers who make essentially no urolithin A regardless of how much pomegranate they consume. These ratios were documented in a landmark 2017 study by Singh et al. in Cell Metabolism and have been replicated in subsequent research.

The tri-modal distribution is not random. It is driven primarily by gut microbiome composition, which varies based on antibiotic history, diet, geography, and age. Non-producers can eat pomegranate daily and experience no meaningful urolithin A in their bloodstream. High producers may benefit substantially from dietary sources. The problem is that most people do not know which group they are in — and there is no consumer test for urolithin A production status.

This is where the supplement story begins. Timeline Biosciences developed Mitopure — a high-purity, standardized urolithin A compound that bypasses the gut conversion step entirely. When you supplement with Mitopure, urolithin A is absorbed directly, producing consistent, measurable blood levels regardless of gut microbiome composition. The Mitopure trials are what generated most of the human RCT evidence on urolithin A that now exists in the literature.

The most significant piece of urolithin A research published in recent years is the phase 1 randomized controlled trial by Denk and colleagues, published in Nature Aging on January 5, 2026. The trial enrolled 50 healthy adults aged 45–70 years in a randomized, double-blind, placebo-controlled design. Participants received either 1,000 mg of oral urolithin A (as Mitopure) daily or placebo for 28 days. Assessments occurred at baseline, day 7, and day 28.

The central hypothesis was that if mitochondrial dysfunction drives immune aging — and if urolithin A improves mitochondrial quality through mitophagy — then UA supplementation should produce measurable shifts in immune cell phenotypes consistent with rejuvenation. The hypothesis held.

**CD8+ T cell rejuvenation:** UA supplementation reshaped the CD8+ T cell pool — the immune cells responsible for killing virus-infected cells and cancer cells — toward a youthful, ready-to-respond profile. The UA group showed increased naive-like CD8+ T cells (the precursor population that declines with age and reduces immune flexibility) and increased Ki-67 expression, a marker of cellular proliferation and reinvigoration. Meanwhile, TOX expression — a transcription factor strongly associated with T cell exhaustion — was significantly reduced in the UA group compared to placebo.

**Mitochondrial biogenesis and energy metabolism:** Urolithin A increased mitochondrial content and PGC-1α expression — a master regulator of mitochondrial biogenesis — in immune cells. Single-cell energetic metabolism profiling (SCENITH) showed that UA shifted immune cell energy use toward oxidative phosphorylation, the more efficient energy pathway that characterizes younger, high-performing immune cells. Exhausted or aging immune cells increasingly rely on less efficient glycolytic pathways; this metabolic shift toward OXPHOS is a functional rejuvenation signal.

**Inflammation markers:** Secondary endpoints showed reductions in inflammatory cytokines, consistent with the hypothesis that better mitochondrial quality in immune cells reduces the low-grade inflammatory signaling associated with immunosenescence. CD4+ T cell subsets remained stable, and no serious adverse events were reported.

The clinical significance of this trial is that it provides the first controlled human evidence of UA-driven immune rejuvenation at the cellular level — not just mitochondrial gene expression changes in muscle, but actual phenotypic shifts in the immune cells that protect you from infection and cancer. Published in Nature Aging, it carries the weight of top-tier peer review and joins a growing body of human clinical data that makes urolithin A one of the best-evidenced longevity supplements available.

The Nature Aging immune trial built on several years of earlier human RCT evidence in the muscle and mitochondrial domains. The landmark muscle endurance trial (NCT03464500, published in European Journal of Nutrition 2022) enrolled 88 older adults (ages 65–90) in a randomized, double-blind, placebo-controlled, parallel-arm design. Participants received 500 mg or 1,000 mg Mitopure daily or placebo for 4 months.

Results showed significant dose-dependent improvements in muscle endurance — particularly grip strength and the six-minute walk test — in the 1,000 mg group compared to placebo. Skeletal muscle biopsies confirmed increased mitochondrial gene expression in treated participants, including upregulation of mitophagy signaling pathways and mitochondrial biogenesis markers. This was the first human trial to demonstrate that urolithin A improves both a functional outcome (muscle endurance) and a mechanistic biomarker (mitochondrial gene expression) in older adults.

A systematic review published in ScienceDirect in July 2024 analyzed 5 urolithin A RCTs involving approximately 250 healthy adults across multiple age groups. The review confirmed dose-dependent reductions in inflammatory markers (IL-6, TNF-alpha, CRP), improvements in mitophagy signaling, and general safety across the studied dose range (500–2,000 mg). No serious adverse events were identified. The review concluded that the weight of evidence supports urolithin A as a safe, bioavailable compound with consistent mitophagy-activating and anti-inflammatory effects in humans — a conclusion that is now further strengthened by the 2026 Nature Aging immune trial.

**Why this evidence base matters:** Spermidine, the other major food-derived mitophagy activator, has a longer history in the basic science literature but fewer human RCTs confirming functional outcomes. See /blog/spermidine-for-autophagy-and-longevity for the full spermidine breakdown. Urolithin A has more controlled human trial evidence at this point — particularly trials with functional endpoints (muscle endurance, immune cell phenotyping) rather than biomarker changes alone. This is a meaningful distinction for people trying to evaluate which compounds actually do something measurable in the body.

Urolithin A and spermidine are both naturally derived compounds that activate cellular recycling pathways, and both are candidates for longevity supplementation. But they operate through different mechanisms, have different evidence profiles, and serve different purposes in a longevity stack. Understanding the distinction prevents redundant supplementation and helps you make a rational stacking decision.

**Mechanism:** Urolithin A works primarily through PINK1/Parkin mitophagy — the pathway specifically responsible for tagging and removing damaged mitochondria. It also activates DAF-16/FOXO and AMP-activated protein kinase (AMPK) pathways. Spermidine activates general autophagy through mTOR inhibition and downstream autophagy gene expression — a broader but less mitochondria-specific mechanism. Spermidine also has direct epigenetic effects (inhibiting histone acetyltransferases) that influence gene expression in ways UA does not.

**Human evidence:** Urolithin A currently has 5+ randomized controlled trials in humans with functional endpoints — including muscle endurance, immune cell rejuvenation, and inflammatory markers. Spermidine has fewer human RCTs with functional endpoints, though observational cohort data linking dietary polyamine intake to longevity is substantial. For someone who wants compound-specific clinical trial evidence, urolithin A currently leads.

**Dietary sourcing:** Spermidine is more accessible through food — wheat germ, soybeans, mushrooms, and aged cheese are high sources, and dietary intake correlates with gut levels more predictably than urolithin A because spermidine is absorbed directly without gut microbiome conversion. UA requires the Gordonibacter conversion step that 60% of people cannot complete effectively from food alone.

**Complementarity:** Urolithin A and spermidine target overlapping but distinct autophagy pathways — mitophagy-specific versus general autophagy. This means combining them is not redundant in the way that stacking two NAD+ precursors would be. A protocol that includes both UA (for mitophagy) and spermidine (for broad autophagy + epigenetic effects) is mechanistically logical and is used by some longevity-focused clinicians. The practical constraint is cost — high-dose Mitopure runs $60–90/month, and quality spermidine supplements add another $40–60/month. Budget accordingly. See /blog/spermidine-for-autophagy-and-longevity for the full spermidine protocol breakdown.

**The practical verdict:** If you can only choose one mitophagy-focused supplement, urolithin A has the stronger clinical trial foundation for functional outcomes in 2026. If you prioritize dietary-first approaches and already eat spermidine-rich foods (wheat germ, aged cheese, mushrooms) regularly, spermidine supplementation may provide less incremental benefit than UA. If budget allows, a combined protocol is mechanistically sound — just ensure you are tracking biomarkers to justify the investment.

The vast majority of human clinical data on urolithin A uses Mitopure — Timeline Biosciences' purified urolithin A compound — at doses of 500 mg, 1,000 mg, or 2,000 mg daily. The 2026 Nature Aging immune trial used 1,000 mg daily for 28 days. The muscle endurance RCT used both 500 mg and 1,000 mg; the 1,000 mg group showed stronger results. The dose-response relationship appears to be real, and 1,000 mg/day is the dose most supported by the current evidence base for longevity-relevant outcomes.

**Forms available:** Mitopure is available as a powder (to be mixed with food or beverages), capsules, and a soft gel format. Third-party brands also sell urolithin A supplements, though quality verification is critical — UA synthesis and purity varies, and most third-party products have not been used in clinical trials. For the intervention most likely to match what was studied, Mitopure is the reference standard. If cost is prohibitive, look for third-party tested urolithin A supplements with verified purity and at least 500 mg per serving.

**Timing and co-ingestion:** Urolithin A absorption does not appear to be strongly dependent on food co-ingestion the way fat-soluble compounds like fisetin are. It can be taken with or without food. Consistency matters more than timing — daily supplementation over weeks is what produces the mitochondrial and immune cell changes documented in trials. Taking it at the same time each day (breakfast or lunch are common choices) helps with adherence.

**Duration of use:** The Nature Aging immune trial showed meaningful changes in 28 days. The muscle endurance trial ran 4 months. For longevity purposes, urolithin A is best treated as a continuous daily supplement rather than a cycled compound — unlike senolytics (fisetin/quercetin), which are pulsed because they clear senescent cells in bursts. Mitophagy support is an ongoing maintenance need, not a one-time clearance event. Most clinicians who recommend UA treat it like creatine or omega-3s — something you take consistently, not cyclically.

**What to avoid:** Megadosing above 2,000 mg/day provides no established additional benefit and has not been studied for safety at higher levels. Combining UA with strong mitophagy inhibitors (certain medications that block autophagy pathways) could theoretically blunt the effect, though this has not been formally documented as a clinical interaction. More broadly, UA is well-tolerated and its drug interaction profile is clean — but as with any supplement taken at therapeutic doses, flagging it with your clinician if you are on complex medications is appropriate.

Unlike stimulants or adaptogens, urolithin A does not produce acute, subjectively noticeable effects. It operates at the level of cellular maintenance — improving mitochondrial quality over weeks to months. Measuring whether it is working requires tracking the right downstream signals over the right timeframe.

**Energy and recovery quality:** The most common subjective report from people supplementing with urolithin A for 4–8 weeks is improved sustained energy, particularly in physical activity contexts. This is consistent with the muscle endurance findings — UA supplementers in the 2022 RCT walked further and gripped harder after 4 months. Subjective training recovery and exercise capacity are worth tracking in a simple weekly log before and during supplementation.

**Inflammatory markers:** Reductions in IL-6, TNF-alpha, and CRP were documented across the urolithin A clinical literature. Running a basic inflammatory panel (hs-CRP, complete metabolic panel) at baseline and again after 3–4 months of consistent supplementation gives you a measurable, objective signal. See /blog/blood-tests-for-longevity for the full panel worth tracking as part of any longevity stack. Note that many other interventions also lower these markers — the signal is real but not uniquely attributable to UA without careful controls.

**Biological age clocks:** Epigenetic aging clocks measure DNA methylation patterns that correlate with biological age. If mitochondrial quality and inflammaging are major drivers of biological aging (strong mechanistic evidence supports this), then urolithin A's effects should show up in epigenetic clock trajectories over 12+ months of consistent use. No published UA-specific epigenetic clock RCT exists yet, but the mechanistic case for eventual clock improvement is strong. See /blog/biological-age-testing-guide for the testing options available and how to establish a baseline.

**Immune function markers:** The Nature Aging RCT measured CD8+ T cell phenotyping and mitochondrial activity — neither of which is easily accessible to consumers. A practical proxy is functional immune resilience: fewer and shorter upper respiratory infections over a 6–12 month window, improved vaccine response (if timed around an annual flu shot), and faster recovery from mild illnesses. These are imperfect but observable signals over a meaningful time window.

**Realistic expectations:** Most people who stick with 1,000 mg/day for 3–6 months report gradually improving training recovery, stable or improving energy levels, and — in those who test — modest improvements in inflammatory markers. The longevity effect is longer-horizon and harder to attribute directly. The honest framing is that urolithin A is an investment in mitochondrial quality that pays dividends on the decadal timescale, not the weekly one.

The urolithin A safety record across human RCTs is consistently clean. No serious adverse events have been attributed to UA supplementation at doses up to 2,000 mg/day in published trials. The most commonly reported minor effects are mild GI symptoms — occasional loose stools or stomach discomfort — in a small subset of participants, typically dose-dependent and transient. These are more common at higher doses and usually resolve within the first two weeks of supplementation.

**Drug interactions:** Urolithin A does not appear to have significant interactions with cytochrome P450 enzymes at supplemental doses — a meaningful safety advantage compared to high-dose fisetin and quercetin. No major drug interactions have been flagged in clinical trial monitoring. That said, UA acts as an autophagy and mitophagy inducer, which has theoretical implications for compounds that depend on autophagic pathways (either accelerating their clearance or competing for autophagy resources). If you are on immunosuppressant medications that target autophagy or mTOR pathways (rapamycin analogs, certain chemotherapeutics), discuss UA with your prescribing clinician.

**Who should check first:** Pregnancy and breastfeeding — no safety data exists at supplemental doses. Active cancer treatment — do not modify autophagy pathways without oncologist guidance. Organ transplant recipients on immunosuppression — any autophagy modulator warrants physician review. Those on polypharmacy regimens with complex medication interactions — standard precaution applies. Otherwise healthy adults with no complex medical background are well within the documented safety profile.

**The supplement quality problem:** Because Mitopure has become the recognized brand name, the supplement market now has many third-party urolithin A products of variable quality. Look for: certificate of analysis from a third-party testing lab, verified urolithin A content (not just ellagitannin complex that relies on your gut to convert), and a standardized dose (at least 500 mg per serving). Pomegranate extract supplements, unless specifically standardized for urolithin A content, are not a reliable UA source for the reasons explained in the conversion section above.

**The bottom line:** Urolithin A is one of the safer longevity supplements relative to its evidence base. The risk profile is low for otherwise healthy adults, the clinical trial monitoring has been rigorous, and no significant safety signals have emerged across multiple independent research groups. For most people, the barrier is cost rather than safety.

Urolithin A is not a foundation supplement — it is a precision layer added on top of behavioral and metabolic fundamentals. Before adding any mitophagy compound, the more impactful longevity behaviors should be in place: resistance training, cardiovascular fitness (particularly Zone 2 work), quality sleep, adequate protein intake, and metabolic health management. These produce compounding effects on mitochondrial quality and immune function that no supplement can replicate. See /blog/strength-training-after-40-longevity for the training framework most directly relevant to the same biological aging targets UA addresses.

Within a supplement stack, urolithin A occupies a specific and non-redundant niche. It does not overlap with NAD+ precursors (NMN, NR) — those support the sirtuin and PARP pathways rather than directly inducing mitophagy. See /blog/nad-supplementation-guide-longevity for the NAD+ breakdown. It partially overlaps with spermidine in the autophagy space but through distinct mechanisms. It does not overlap with omega-3s, creatine, vitamin D, or magnesium. This means UA can be cleanly stacked with most common longevity supplements.

**Suggested sequencing for someone building a longevity stack:** Establish the behavioral foundation (training, sleep, protein). Run a blood panel baseline (see /blog/blood-tests-for-longevity). Add tier-one supplements with the strongest evidence — omega-3s, creatine, vitamin D if deficient, magnesium (see /blog/best-longevity-supplements-evidence for the ranked overview). Once this foundation is stable and measured over 3–6 months, adding urolithin A at 1,000 mg/day is a high-signal next layer, particularly for adults over 40 experiencing declining energy, recovery quality, or immune resilience.

**The 2026 market context:** Timeline Biosciences has expanded Mitopure availability significantly, and multiple supplement companies now sell urolithin A. The compound has crossed from niche research circles into mainstream longevity supplement stacks. This mainstreaming brings more consumer awareness but also more marketing noise — the core discipline remains the same: prioritize products with third-party testing, verify UA content (not ellagitannin precursors), and track your own biomarkers over time to assess whether the investment is producing the effects the research predicts.

**What is the best urolithin A supplement?** Mitopure by Timeline Biosciences is the reference standard — it is the form used in published human RCTs and the only product with a verified, consistent UA concentration matched to clinical trial doses. Third-party urolithin A supplements are emerging but should be evaluated against certificate of analysis data. Pomegranate extracts and ellagitannin supplements are not reliable UA sources unless specifically standardized for urolithin A content.

**How long does urolithin A take to work?** The Nature Aging immune trial showed meaningful shifts in CD8+ T cell profiles by day 28. The muscle endurance trial showed significant functional improvements after 4 months. For longevity biomarkers, expect a 3–6 month window to see meaningful trends. Acute effects are subtle — if you are waiting to 'feel' something dramatic in week one, you will be disappointed. The mechanism is maintenance-level, not stimulant-level.

**Can I get enough urolithin A from pomegranate juice?** Only if you are a high producer — roughly 40% of people. The majority of the population (60%) will generate insufficient urolithin A from dietary sources regardless of pomegranate intake, due to gut microbiome composition. If you do not know your producer status, direct UA supplementation guarantees the clinical-trial-matched dose regardless of your microbiome.

**Is urolithin A the same as urolithin B?** No. Urolithin A (UA) and urolithin B (UB) are related but distinct compounds produced by different gut microbiome conversion pathways. Urolithin A is the primary compound studied for mitophagy induction and has the most human clinical trial evidence. Urolithin B has some evidence of its own but is less studied and not the form used in the major RCTs. When evaluating supplements, confirm they contain urolithin A specifically.

**Should I take urolithin A if I already take spermidine?** Both compounds support autophagy/mitophagy through different mechanisms, and they are mechanistically complementary rather than redundant. If budget allows, the combination is rational. If you can only choose one, urolithin A currently has stronger functional clinical trial evidence. If you already get significant dietary spermidine from wheat germ and aged cheese, UA supplementation provides more incremental benefit than adding more spermidine would.

**Does urolithin A require cycling like senolytics?** No. Unlike fisetin and quercetin, which are used in pulsed cyclic protocols designed to mimic a burst clearance model, urolithin A works best as a continuous daily supplement. Mitophagy is an ongoing maintenance function — not a one-time event — and the benefits documented in the muscle endurance and immune aging trials were produced by consistent daily supplementation over weeks to months.

Urolithin A has the kind of human clinical trial evidence that most longevity supplements lack: multiple randomized controlled trials, functional endpoints (not just biomarkers), a clean safety record, and a publication in Nature Aging. Yet it remains significantly less discussed than NMN, resveratrol, or berberine — compounds with thinner or more contested human data. That gap will close as the research profile continues to build, but early adopters of well-evidenced interventions have a window to establish years of mitophagy support before UA becomes mainstream knowledge.

The mechanism is sound. The evidence is real. The production gap in dietary sourcing means most people are not getting meaningful UA from food. And the biomarkers it affects — mitochondrial quality, immune cell phenotype, inflammatory markers, and ultimately biological age trajectories — are exactly the downstream targets that define healthspan.

Take the AliveLongevity healthspan quiz at alivelongevity.com/quiz/healthspan to get a personalized supplement priority stack based on your current health profile. Urolithin A may or may not be your highest-priority next addition — for some people, getting sleep, protein, and training right will produce larger biological aging effects than any supplement. The quiz will help you identify your highest-leverage gap and stack accordingly. See /start-here for the full foundational framework.

**Further reading:** /blog/spermidine-for-autophagy-and-longevity to compare the two leading dietary mitophagy compounds, /blog/biological-age-testing-guide to set up your measurement baseline, /blog/blood-tests-for-longevity for the inflammatory marker panel worth tracking, and /blog/strength-training-after-40-longevity for the training foundation that amplifies every supplement you add on top of it.

**Disclaimer:** AliveLongevity content is educational and does not constitute medical advice. Urolithin A supplements are not FDA-approved to treat or prevent any disease. Results from clinical trials may not apply to all individuals. Always consult a qualified clinician before starting any supplement protocol, particularly if you have active health conditions or take prescription medications.